Brief: Altamira Therapeutics Files Second Provisional Patent Application For Oligophore Nanoparticles Targeting Different Kras Mutations In Cancer Treatment
24/01/2024 16:11
Jan 24 (Reuters) - Altamira Therapeutics Ltd CYTO.O :
* ALTAMIRA THERAPEUTICS FILES SECOND PROVISIONAL PATENT
APPLICATION FOR OLIGOPHORE NANOPARTICLES TARGETING DIFFERENT
KRAS MUTATIONS IN CANCER TREATMENT
Source text for Eikon: ID:nGNXHplg0
Further company coverage: CYTO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Altamira Therapeutics
See all newsBrief: Altamira Therapeutics Reports Full Year 2024 Results
Brief: Altamira Therapeutics Announces Transition From Nasdaq To OTC Markets
Brief: Altamira Therapeutics Provides Update On Nasdaq Listing
Brief: Altamira Therapeutics Provides Business Update And First Half 2024 Financial Results
Brief: Altamira Therapeutics Announces Pricing Of Up To $12.0 Mln Public Offering